Shen DD - Search Results

1

First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.

Fisher JM, Wrighton SA, Watkins PB, Schmiedlin-Ren P, Calamia JC, Shen DD, Kunze KL, Thummel KE. Fisher JM, et al. Among authors: shen dd. J Pharmacol Exp Ther. 1999 May;289(2):1134-42. J Pharmacol Exp Ther. 1999. PMID: 10215697

2

Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding.

Fisher JM, Wrighton SA, Calamia JC, Shen DD, Kunze KL, Thummel KE. Fisher JM, et al. Among authors: shen dd. J Pharmacol Exp Ther. 1999 May;289(2):1143-50. J Pharmacol Exp Ther. 1999. PMID: 10215698

3

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, et al. Thummel KE, et al. Among authors: shen dd. J Pharmacol Exp Ther. 1994 Oct;271(1):549-56. J Pharmacol Exp Ther. 1994. PMID: 7965755

4

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, et al. Thummel KE, et al. Among authors: shen dd. J Pharmacol Exp Ther. 1994 Oct;271(1):557-66. J Pharmacol Exp Ther. 1994. PMID: 7965756

5

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Thummel KE, et al. Among authors: shen dd. Clin Pharmacol Ther. 1996 May;59(5):491-502. doi: 10.1016/S0009-9236(96)90177-0. Clin Pharmacol Ther. 1996. PMID: 8646820 Clinical Trial.

6

First-pass metabolism of midazolam by the human intestine.

Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. Paine MF, et al. Among authors: shen dd. Clin Pharmacol Ther. 1996 Jul;60(1):14-24. doi: 10.1016/S0009-9236(96)90162-9. Clin Pharmacol Ther. 1996. PMID: 8689807

7

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

Gibbs MA, Thummel KE, Shen DD, Kunze KL. Gibbs MA, et al. Among authors: shen dd. Drug Metab Dispos. 1999 Feb;27(2):180-7. Drug Metab Dispos. 1999. PMID: 9929500

8

Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.

Gibbs MA, Baillie MT, Shen DD, Kunze KL, Thummel KE. Gibbs MA, et al. Among authors: shen dd. Pharm Res. 2000 Mar;17(3):299-305. doi: 10.1023/a:1007550717526. Pharm Res. 2000. PMID: 10801218

9

The human CYP3A subfamily: practical considerations.

Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. Wrighton SA, et al. Among authors: shen dd. Drug Metab Rev. 2000 Aug-Nov;32(3-4):339-61. doi: 10.1081/dmr-100102338. Drug Metab Rev. 2000. PMID: 11139133 Review. No abstract available.

10

Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Paine MF, et al. Among authors: shen dd. J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62. J Pharmacol Exp Ther. 1997. PMID: 9400033

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

301 results

Search Page

Filters